

***Core indicators for monitoring the Ending the HIV Epidemic initiative
(preliminary data): National HIV Surveillance System data reported
through June 2022; and preexposure prophylaxis (PrEP) data reported
through March 2022***

Advisory Statement

Effective date: May 21, 2024

Publication date of referenced document: September 2022

Preexposure prophylaxis (PrEP) coverage is currently estimated by taking the number of persons prescribed PrEP (numerator) and dividing it by the estimated number of persons with indications for PrEP (denominator). Since the current methodology for estimating PrEP coverage was first published in 2018, CDC has cited limitations of both the numerator and denominator. For example, the number of persons prescribed PrEP is estimated by using data from the IQVIA pharmacy database based on an algorithm that includes FDA-approved drugs for PrEP. Although IQVIA records 94% of all prescriptions from retail pharmacies and 74% from mail-order outlets in the United States, data from closed health care systems are not included in the IQVIA data set. Therefore, the current PrEP numerator has represented minimum estimates of PrEP prescriptions. Additionally, race/ethnicity data in the IQVIA database are only available for <40% of persons prescribed PrEP each year. Regarding limitations of the current denominator, the number of persons who have indications for PrEP is estimated by using data from 3 sources: National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Each of these data sources have different schedules of data availability. As a result, the availability of a denominator often lags the availability of a numerator.

In March 2024, updated data from 2 closed-system sources were made available to CDC that can improve the representativeness of the number of persons prescribed PrEP in the United States. In the coming months, CDC also expects to have updates to the data sets currently used to estimate the number of persons with indications for PrEP. To ensure that PrEP coverage estimates are calculated using the best available data at the time of publication, CDC is pausing PrEP coverage reporting for one year. During this time, CDC will update PrEP coverage data sources and determine the best way to present PrEP coverage. CDC plans to resume PrEP coverage reporting in the next HIV Surveillance Supplemental (Monitoring) Report, currently scheduled for publication in June 2025.

Until updated estimates are published, CDC advises against citing specific PrEP coverage data points and instead recommends referencing general trends and disparities. In addition, because of a formula error that affects a subset of race and ethnicity PrEP data, race and ethnicity data points from all reports published prior to 2024 should not be cited.

HIV SURVEILLANCE DATA TABLES



**Core Indicators for Monitoring the Ending the
HIV Epidemic Initiative (*Preliminary Data*):**

**National HIV Surveillance System Data Reported
through June 2022; and Preexposure Prophylaxis
(PrEP) Data Reported through March 2022**



**Centers for Disease
Control and Prevention**
National Center for HIV,
Viral Hepatitis, STD, and
TB Prevention

This issue of *HIV Surveillance Data Tables* is published by the Division of HIV Prevention (DHP), National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, Georgia.

Data are presented for diagnoses of HIV infection reported to CDC through June 2022 and preexposure prophylaxis (PrEP) data reported through March 2022.

HIV Surveillance Data Tables is not copyrighted and may be used and copied without permission. Citation of the source is, however, appreciated.

Suggested citation

Centers for Disease Control and Prevention. Core indicators for monitoring the Ending the HIV Epidemic initiative (preliminary data): National HIV Surveillance System data reported through June 2022; and preexposure prophylaxis (PrEP) data reported through March 2022. *HIV Surveillance Data Tables* 2022;3(3). <https://www.cdc.gov/hiv/library/reports/surveillance-data-tables/>. Published September 2022. Accessed [date].

On the Web: <https://www.cdc.gov/hiv/library/reports/surveillance-data-tables/>

Confidential information, referrals, and educational material on HIV infection

CDC-INFO

1-800-232-4636 (in English, en Español)

1-888-232-6348 (TTY)

<http://www.cdc.gov/dcs/ContactUs/Form>

Acknowledgments

HIV Surveillance Data Tables was prepared by the following staff and contractors of the Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC: Anna Satcher Johnson, Zanetta Gant, Ya-lin Huang, Weiming Zhu, Dawn Smith, Jianmin Li, Xiaohong Hu, Hao Chang, Pei Hou, Shawn McCort, Chelsea Walker, Emily Zhu, Lei Yu, Ishwarya Ravichandran, Avery Smithson, Wei Wei, Iddrisu Abdallah, Norma Harris, and Michael Friend (editing and desktop publishing).

The Web and Consumer Services Team of the Prevention Communications Branch are acknowledged for their contributions to the report website.

Publication of *HIV Surveillance Data Tables* was made possible by the contributions of the state and territorial health departments and the HIV surveillance programs that provided surveillance data to CDC.

Contents

Technical Notes	4
References	6
Tables	
1a Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, January 2021 through June 2022—United States (preliminary)	7
1b Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, January 2021 through June 2022—United States and 6 dependent areas (preliminary)	8
1c Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, January 2021 through June 2022—United States and 6 dependent areas (preliminary)	9
1d Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, January 2021 through June 2022—Ending the HIV Epidemic Phase I jurisdictions (preliminary)	10
2a Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥ 13 years, by selected characteristics, January 2021 through March 2022—45 states and the District of Columbia (preliminary)	12
2b Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥ 13 years, by area of residence, January 2021 through March 2022—45 states and the District of Columbia (preliminary)	14
2c Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥ 13 years, by area of residence, January 2021 through March 2022—Ending the HIV Epidemic Phase I jurisdictions (preliminary)	16
3a Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through March 2022, among persons aged ≥ 16 years, by selected characteristics—United States (preliminary)	20
3b Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through March 2022, among persons aged ≥ 16 years, by area of residence—United States and Puerto Rico (preliminary)	22
3c Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through March 2022, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (preliminary)	26
4 Ending the HIV Epidemic Phase I jurisdictions	34

Technical Notes

The *Ending the HIV Epidemic in the U.S. (EHE)* initiative leverages critical scientific advances in HIV prevention, diagnosis, treatment, and outbreak response [1]. The goal of the initiative is to reduce new HIV infections by 75% by 2025 and then by at least 90% by 2030. The Centers for Disease Control and Prevention (CDC) routinely releases *HIV Surveillance Data Tables* on the core indicators for EHE to allow for more timely monitoring of progress. The full list of EHE core indicators and their definitions can be found in the Technical Notes of the *Core Indicators for Monitoring the Ending the HIV Epidemic Initiative* report at <https://www.cdc.gov/hiv/pdf/library/reports/surveillance-data-tables/vol-1-no-1/cdc-hiv-surveillance-tables-vol-1-no-1.pdf>.

The tables included in this report provide preliminary data on HIV diagnoses and linkage to HIV medical care reported to CDC as of June 2022 for the years 2021 and 2022, and data on preexposure prophylaxis (PrEP) coverage for the years 2019, 2020, 2021, and 2022 (preliminary). Data for the 3 indicators are provided at the national, state, and county levels (EHE Phase I jurisdictions only). See Tabulation and Presentation of Data for details on how the indicators are calculated.

TABULATION AND PRESENTATION OF DATA

Diagnoses of HIV Infection

Diagnoses of HIV infection are the numbers of persons aged ≥ 13 years with HIV diagnosed during January 2021 through June 2022 (Tables 1a–d). Data presented were reported (after the removal of personally identifiable information) to CDC.

An evaluation of surveillance data (2015–2019 diagnoses) found that, on average, approximately 75% of HIV diagnoses are reported to CDC during the year of diagnosis and approximately 95% of HIV diagnoses are reported to CDC by the end of the following year. Data reported to the National HIV Surveillance System (NHSS) are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

More information on counting diagnoses of HIV infection can be found at <https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-33/> (*HIV Surveillance Report, 2020*).

Linkage to HIV Medical Care

Linkage to HIV medical care within 1 month of HIV diagnosis is measured for persons aged ≥ 13 years whose infection was diagnosed during January 2021 through March 2022 and who resided in any of the jurisdictions (including EHE Phase I jurisdictions) with complete reporting of laboratory data to CDC at the time of diagnosis (Tables 2a–c). The numerator is the number of persons aged ≥ 13 years whose HIV infection was diagnosed during January 2021 through March 2022 and who had ≥ 1 CD4 T-lymphocyte (CD4) or viral load (VL) tests within 1 month of HIV diagnosis. The denominator is the number of persons aged ≥ 13 years whose HIV infection was diagnosed during January 2021 through March 2022. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting delay to account for delays in reporting of laboratory results to NHSS; therefore, data on linkage to HIV medical care in these surveillance tables are for persons whose HIV infection was diagnosed during January 2021 through March 2022 and was reported to NHSS through June 2022. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: Kentucky, New Jersey, Pennsylvania (excluding Philadelphia), Puerto Rico, and Vermont.

Data reported to NHSS are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

More information on calculating linkage to care can be found at <https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-27-no-3/> (*Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2020*).

Preexposure Prophylaxis Coverage

Preexposure prophylaxis (PrEP) coverage, reported as a percentage, is defined as the number of persons aged ≥ 16 years classified as having been prescribed PrEP during the specified year divided by the estimated number of persons aged ≥ 16 years who had indications for PrEP during the specified year (Tables 3a–c). PrEP coverage is an EHE indicator that is not a

reportable disease or condition and is not reported to NHSS. Multiple data sources, described below, are used to calculate PrEP coverage.

Please use caution when interpreting PrEP data. Different data sources were used in the numerator and denominator to calculate PrEP coverage.

Persons prescribed PrEP

National pharmacy data from the IQVIA Real World Data—Longitudinal Prescriptions database (hereafter, IQVIA database) are used to classify persons aged ≥ 16 years who have been prescribed PrEP in the specific year. The IQVIA database captures prescriptions from all payers and represents approximately 93% of all prescriptions from retail pharmacies and 77% from mail-order outlets in the United States. The database does not include prescriptions from some closed health care systems that do not make their prescription data available to IQVIA. Therefore, these are minimum estimates of PrEP coverage. The annual number of persons classified as having been prescribed PrEP was based on a validated algorithm that discerns whether tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) was prescribed for PrEP after excluding prescriptions for HIV treatment, hepatitis B treatment, or HIV postexposure prophylaxis [2–4]. Tenofovir alafenamide and emtricitabine (TAF/FTC) was approved as an alternative drug for PrEP by the U.S. Food and Drug Administration (FDA) in October 2019. Starting in 2019, TAF/FTC was included in the algorithm to classify the number of persons prescribed PrEP.

The number of persons classified as having been prescribed PrEP is reported by sex, age group, and race/ethnicity. Transmission category data are not available in the IQVIA database, and race/ethnicity data are available for $<40\%$ of persons with PrEP prescriptions. Please use caution when interpreting PrEP data by race/ethnicity. Race/ethnicity categories available in the IQVIA database include White, Black/African American, Hispanic/Latino, and other. The number of persons prescribed PrEP for each racial/ethnic group presented in this report was extrapolated by applying the racial/ethnic distribution of known records to those for which data on race/ethnicity were unknown.

Geographic designations

In the IQVIA database, a person's location is reported as a 3-digit ZIP code prefix (hereafter, ZIP3) assigned

by the U.S. Postal Service. To estimate the number of persons prescribed PrEP at the state or county level, a probability-based approach is used to crosswalk between ZIP3s and states/counties by using data from (a) the U.S. Census Bureau's American Community Survey (ACS) 5-year estimates by ZIP Code Tabulation Areas (ZCTAs) [5], and (b) the U.S Department of Housing and Urban Development's ZIP Code Crosswalk Files [6]. Because of reliability concerns, subnational estimates of <40 are not included.

Persons with PrEP indications

ACS and U.S. Census Bureau files were used to estimate the number of men who have sex with men (MSM) in a jurisdiction [7, 8]. Next, behavioral data from the National Health and Nutrition Examination Survey (NHANES) were used to estimate the proportion of HIV-negative MSM with indications for PrEP [9].

The number of HIV-negative MSM with indications for PrEP was multiplied by the ratio of percentage of diagnoses during the specified year attributed to other major transmission risk groups compared to the percentage among MSM in a given state or county. The estimated numbers of persons with indications for PrEP in the 3 major transmission risk groups (MSM, heterosexuals, persons who inject drugs) in each jurisdiction were then summed to yield a state- or county-specific estimate. State estimates were then summed for a national total of persons with indications for PrEP [7]. Jurisdictional estimates were rounded to the nearest 10.

The tables included in this report provide updated data on PrEP coverage for the years 2019–March 2022 by using the IQVIA data reported through December 2021. IQVIA conducts data quality assurance activities. As a result, the number of persons classified as having been prescribed PrEP in a given year might change from time to time. The impact of the changes may vary by demographic category nationally and by jurisdiction. The data sources used to estimate the number of persons with indications for PrEP have different schedules of availability. Consequently, the availability of a denominator lags the availability of a numerator by approximately 1 year. PrEP coverage data with a lagged denominator are considered preliminary.

For this release of *HIV Surveillance Data Tables*, 2018 denominators were used for 2019, 2020, 2021, and 2022 PrEP coverage data; consequently, 2019

through March 2022 PrEP coverage data are considered preliminary. In addition to being preliminary, data for the year 2020 should be interpreted with awareness of the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions [10].

More information on calculating PrEP coverage can be found at <https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-27-no-3/> (*Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2020*).

9. CDC [Smith DK, Van Handel M, Wolitski RJ, et al]. Vital Signs: Estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition—United States, 2015. *MMWR* 2015;64(46):1291–1295. doi:10.15585/mmwr.mm6446a4
10. Huang YA, Zhu W, Wiener J, Kourtis AP, Hall HI, Hoover KW. Impact of COVID-19 on HIV preexposure prophylaxis prescriptions in the United States—a time series analysis. *Clin Infect Dis* 2022:ciac038. doi:10.1093/cid/ciac038

REFERENCES

1. HHS. What is *Ending the HIV Epidemic in the U.S.?* <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview>. Updated July 2, 2022. Accessed August 31, 2022.
2. Wu H, Mendoza MC, Huang YA, Hayes T, Smith DK, Hoover KW. Uptake of HIV preexposure prophylaxis among commercially insured persons—United States, 2010–2014. *Clin Infect Dis* 2017;64(2):144–149. doi:10.1093/cid/ciw701
3. CDC [Huang YA, Zhu W, Smith DK, Harris N, Hoover KW]. HIV preexposure prophylaxis, by race and ethnicity—United States, 2014–2016. *MMWR* 2018;67(41):1147–1150. doi:10.15585/mmwr.mm6741a3
4. Furukawa NW, Smith DK, Gonzalez CJ, et al. Evaluation of algorithms used for PrEP surveillance using a reference population from New York City, July 2016–June 2018. *Public Health Rep* 2020;135(2):202–210. doi:10.1177/0033354920904085
5. U.S. Census Bureau. American Community Survey 5-year data (2009–2020). <https://www.census.gov/data/developers/data-sets/acs-5year.2019.html>. Published March 2022. Accessed August 31, 2022.
6. U.S. Department of Housing and Urban Development (HUD). HUD USPS ZIP code crosswalk files. https://www.huduser.gov/portal/datasets/usps_crosswalk.html. Updated August 2022. Accessed August 31, 2022.
7. Grey JA, Bernstein KT, Sullivan PS, et al. Estimating the population sizes of men who have sex with men in US states and counties using data from the American Community Survey. *JMIR Public Health Surveill* 2016;2(1):e14. doi:10.2196/publichealth.5365
8. Purcell DW, Johnson CH, Lansky A, et al. Estimating the population size of men who have sex with men in the United States to obtain HIV and syphilis rates. *Open AIDS J* 2012;6:98–107. doi:10.2174/1874613601206010098

Table 1a. Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, January 2021 through June 2022—United States (preliminary)

	2021 No.	2022 (January– June) No.
Gender		
Male	28,103	11,492
Female	6,469	2,572
Transgender woman ^a	761	244
Transgender man ^a	54	15
Additional gender identity ^b	38	15
Age at diagnosis (yr)		
13–24	6,801	2,526
25–34	13,024	5,303
35–44	7,510	3,203
45–54	4,380	1,843
≥55	3,710	1,463
Race/ethnicity		
American Indian/Alaska Native	225	68
Asian	736	303
Black/African American	14,406	5,611
Hispanic/Latino ^c	10,179	4,383
Native Hawaiian/other Pacific Islander	75	36
White	8,963	3,735
Multiracial	841	202
Transmission category (based on sex at birth)^d		
Male-to-male sexual contact	23,818	9,841
Injection drug use		
Male	1,424	523
Female	1,060	410
Male-to-male sexual contact and injection drug use	1,308	447
Heterosexual contacte		
Male	2,315	928
Female	5,402	2,139
Other ^f		
Male	33	12
Female	66	39
Region of residence^g		
Northeast	5,007	1,845
Midwest	4,675	1,817
South	18,793	8,131
West	6,950	2,545
Total	35,425	14,338

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are for cases reported to CDC through June 2022. Data are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

^a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.

^b Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

^c Hispanic/Latino persons can be of any race.

^d Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column totals. Data include transgender and additional gender identity persons.

^e Sexual contact with a person known to have, or with a risk factor for, HIV infection.

^f Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.

^g Data are based on residence at time of diagnosis of HIV infection.

Table 1b. Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, January 2021 through June 2022—United States and 6 dependent areas (preliminary)

	2021	2022 (January– June)
	No.	No.
Gender		
Male	28,435	11,588
Female	6,545	2,598
Transgender woman ^a	761	244
Transgender man ^a	54	15
Additional gender identity ^b	38	15
Age at diagnosis (yr)		
13–24	6,859	2,536
25–34	13,143	5,349
35–44	7,600	3,233
45–54	4,455	1,862
≥55	3,776	1,480
Race/ethnicity		
American Indian/Alaska Native	225	68
Asian	737	303
Black/African American	14,409	5,611
Hispanic/Latino ^c	10,580	4,502
Native Hawaiian/other Pacific Islander	75	36
White	8,966	3,738
Multiracial	841	202
Transmission category (based on sex at birth)^d		
Male-to-male sexual contact	24,065	9,914
Injection drug use		
Male	1,443	528
Female	1,062	411
Male-to-male sexual contact and injection drug use	1,310	449
Heterosexual contact ^e		
Male	2,378	943
Female	5,475	2,164
Other ^f		
Male	34	12
Female	67	39
Region of residence^g		
Northeast	5,007	1,845
Midwest	4,675	1,817
South	18,793	8,131
West	6,950	2,545
U.S. dependent areas	408	122
Total	35,833	14,460

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are for cases reported to CDC through June 2022. Data are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

^a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.

^b Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

^c Hispanic/Latino persons can be of any race.

^d Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column totals. Data include transgender and additional gender identity persons.

^e Sexual contact with a person known to have, or with a risk factor for, HIV infection.

^f Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.

^g Data are based on residence at time of diagnosis of HIV infection.

Table 1c. Diagnoses of HIV infection among persons aged ≥13 years, by area of residence, January 2021 through June 2022—United States and 6 dependent areas (preliminary)

Area of residence	2021	2022 (January– June)
	No.	No.
Alabama	447	167
Alaska	30	8
Arizona	799	371
Arkansas	344	156
California	4,139	1,357
Colorado	404	187
Connecticut	230	88
Delaware	80	46
District of Columbia	197	32
Florida	4,609	2,797
Georgia	2,168	758
Hawaii	64	18
Idaho	54	12
Illinois	1,051	373
Indiana	529	255
Iowa	124	44
Kansas	155	60
Kentucky	389	154
Louisiana	934	466
Maine	31	14
Maryland	755	331
Massachusetts	437	89
Michigan	633	280
Minnesota	299	110
Mississippi	425	129
Missouri	547	218
Montana	22	5
Nebraska	106	43
Nevada	496	183
New Hampshire	32	12
New Jersey	1,152	477
New Mexico	148	21
New York	2,123	790
North Carolina	1,395	646
North Dakota	36	1
Ohio	909	320
Oklahoma	375	105
Oregon	198	129
Pennsylvania	922	364
Rhode Island	67	11
South Carolina	667	211
South Dakota	30	6
Tennessee	833	360
Texas	4,226	1,334
Utah	131	23
Vermont	13	0
Virginia	801	379
Washington	458	226
West Virginia	148	60
Wisconsin	256	107
Wyoming	7	5
Subtotal	35,425	14,338
U.S. dependent areas		
American Samoa	0	0
Guam	1	0
Northern Mariana Islands	0	0
Puerto Rico	402	122
Republic of Palau	0	0
U.S. Virgin Islands	5	0
Subtotal	408	122
Total	35,833	14,460

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at diagnosis of HIV infection. Data are for cases reported to CDC through June 2022. Data are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

Table 1d. Diagnoses of HIV infection among persons aged ≥13 years, by area of residence, January 2021 through June 2022—Ending the HIV Epidemic Phase I jurisdictions (preliminary)

Area of residence	2021	2022 (January– June)
	No.	No.
Arizona		
Maricopa County	526	257
California		
Alameda County	186	79
Los Angeles County	1,381	429
Orange County	265	103
Riverside County	245	118
Sacramento County	150	22
San Bernardino County	295	83
San Diego County	285	6
San Francisco County	188	94
District of Columbia	197	32
Florida		
Broward County	652	385
Duval County	295	133
Hillsborough County	315	190
Miami-Dade County	1,201	773
Orange County	455	270
Palm Beach County	317	163
Pinellas County	127	85
Georgia		
Cobb County	143	40
DeKalb County	312	107
Fulton County	528	197
Gwinnett County	138	41
Illinois		
Cook County	748	258
Indiana		
Marion County	217	97
Louisiana		
East Baton Rouge Parish	149	67
Orleans Parish	147	71
Maryland		
Baltimore City	159	81
Montgomery County	100	40
Prince George's County	231	94
Massachusetts		
Suffolk County	128	26
Michigan		
Wayne County	251	110
Nevada		
Clark County	442	162
New Jersey		
Essex County	263	99
Hudson County	161	81

Table 1d. Diagnoses of HIV infection among persons aged ≥13 years, by area of residence, January 2021 through June 2022—Ending the HIV Epidemic Phase I jurisdictions (preliminary) (cont)

Area of residence	2021	2022 (January– June)
	No.	No.
New York		
Bronx County	419	145
Kings County	439	164
New York County	324	130
Queens County	336	119
North Carolina		
Mecklenburg County	278	116
Ohio		
Cuyahoga County	165	52
Franklin County	187	54
Hamilton County	124	39
Pennsylvania		
Philadelphia County	369	147
Puerto Rico		
San Juan Municipio	97	32
Tennessee		
Shelby County	298	133
Texas		
Bexar County	333	116
Dallas County	780	287
Harris County	1,143	422
Tarrant County	308	106
Travis County	226	78
Washington		
King County	219	136

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at diagnosis of HIV infection.

Data are for cases reported to CDC through June 2022.

Data are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

Table 2a. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by selected characteristics, January 2021 through March 2022—45 states and the District of Columbia (preliminary)

	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
		No.	%	No.	%
	2021				
Gender					
Male	26,154	21,561	82.4	4,593	17.6
Female	5,930	4,875	82.2	1,055	17.8
Transgender woman ^a	725	610	84.1	115	15.9
Transgender man ^a	52	48	92.3	4	7.7
Additional gender identity ^b	34	29	85.3	5	14.7
Age at diagnosis (yr)					
13–24	6,378	5,125	80.4	1,253	19.6
25–34	12,118	9,982	82.4	2,136	17.6
35–44	6,947	5,764	83.0	1,183	17.0
45–54	4,028	3,374	83.8	654	16.2
≥55	3,424	2,878	84.1	546	15.9
Race/ethnicity					
American Indian/Alaska Native	222	181	81.5	41	18.5
Asian	692	610	88.2	82	11.8
Black/African American	13,387	10,710	80.0	2,677	20.0
Hispanic/Latino ^c	9,504	8,116	85.4	1,388	14.6
Native Hawaiian/other Pacific Islander	72	57	79.2	15	20.8
White	8,250	6,808	82.5	1,442	17.5
Multiracial	768	641	83.5	127	16.5
Transmission category (based on sex at birth)^d					
Male-to-male sexual contact	22,351	18,571	83.1	3,780	16.9
Injection drug use	2,216	1,693	76.4	523	23.6
Male	1,254	943	75.2	311	24.8
Female	962	750	78.0	212	22.0
Male-to-male sexual contact and injection drug use	1,210	965	79.8	244	20.2
Heterosexual contact ^e	7,028	5,820	82.8	1,208	17.2
Male	2,065	1,695	82.1	370	17.9
Female	4,963	4,125	83.1	837	16.9
Total^f	32,895	27,123	82.5	5,772	17.5

Table 2a. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by selected characteristics, January 2021 through March 2022—45 states and the District of Columbia (preliminary) (cont)

	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test		
		No.	No.	%	No.	
2022 (January–March)						
Gender						
Male	6,348	5,243	82.6	1,105	17.4	
Female	1,420	1,143	80.5	277	19.5	
Transgender woman ^a	137	118	86.1	19	13.9	
Transgender man ^a	10	9	90.0	1	10.0	
Additional gender identity ^b	9	8	88.9	1	11.1	
Age at diagnosis (yr)						
13–24	1,464	1,168	79.8	296	20.2	
25–34	2,862	2,350	82.1	512	17.9	
35–44	1,716	1,438	83.8	278	16.2	
45–54	1,079	901	83.5	178	16.5	
≥55	803	664	82.7	139	17.3	
Race/ethnicity						
American Indian/Alaska Native	45	34	75.6	11	24.4	
Asian	171	158	92.4	13	7.6	
Black/African American	3,045	2,391	78.5	654	21.5	
Hispanic/Latino ^c	2,522	2,175	86.2	347	13.8	
Native Hawaiian/other Pacific Islander	21	15	71.4	6	28.6	
White	2,003	1,653	82.5	350	17.5	
Multiracial	117	95	81.2	22	18.8	
Transmission category (based on sex at birth)^d						
Male-to-male sexual contact	5,508	4,580	83.2	928	16.8	
Injection drug use	475	371	78.0	105	22.0	
Male	251	191	76.4	59	23.6	
Female	224	179	79.8	45	20.2	
Male-to-male sexual contact and injection drug use	238	189	79.3	49	20.7	
Heterosexual contact ^e	1,676	1,358	81.1	317	18.9	
Male	489	402	82.1	88	17.9	
Female	1,187	957	80.6	230	19.4	
Total^f	7,924	6,521	82.3	1,403	17.7	

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/ μ L) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only]; NHSS, National HIV Surveillance System [footnotes only].

Note. Data are based on residence at diagnosis of HIV infection. Data are for cases reported to CDC through June 2022, are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting delay to account for delays in reporting of laboratory results to NHSS; therefore, data on linkage to HIV medical care in these surveillance tables are for persons with HIV diagnosed during January 2021 through March 2022. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Area without laws: Idaho. Areas with incomplete reporting: Kentucky, New Jersey, Pennsylvania (excluding Philadelphia), and Vermont.

^a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.

^b Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

^c Hispanic/Latino persons can be of any race.

^d Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column totals. Data include transgender and additional gender identity persons.

^e Sexual contact with a person known to have, or with a risk factor for, HIV infection.

^f Includes persons whose infection was attributed to hemophilia, blood transfusion, or perinatal exposure or whose risk factor was not reported or not identified; data not displayed because the numbers were too small to be meaningful.

Table 2b. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2021 through March 2022—45 states and the District of Columbia (preliminary)

Area of residence	Total diagnoses No.	≥1 CD4 or VL tests		No CD4 or VL test	
		No.	%	No.	%
2021					
Alabama	447	335	74.9	112	25.1
Alaska	30	28	93.3	2	6.7
Arizona	799	676	84.6	123	15.4
Arkansas	344	267	77.6	77	22.4
California	4,139	3,475	84.0	664	16.0
Colorado	404	340	84.2	64	15.8
Connecticut	230	201	87.4	29	12.6
Delaware	80	68	85.0	12	15.0
District of Columbia	197	160	81.2	37	18.8
Florida	4,609	3,886	84.3	723	15.7
Georgia	2,168	1,800	83.0	368	17.0
Hawaii	64	54	84.4	10	15.6
Illinois	1,051	898	85.4	153	14.6
Indiana	529	405	76.6	124	23.4
Iowa	124	106	85.5	18	14.5
Kansas	155	141	91.0	14	9.0
Louisiana	934	751	80.4	183	19.6
Maine	31	27	87.1	4	12.9
Maryland	755	659	87.3	96	12.7
Massachusetts	437	399	91.3	38	8.7
Michigan	633	549	86.7	84	13.3
Minnesota	299	246	82.3	53	17.7
Mississippi	425	299	70.4	126	29.6
Missouri	547	426	77.9	121	22.1
Montana	22	20	90.9	2	9.1
Nebraska	106	90	84.9	16	15.1
Nevada	496	433	87.3	63	12.7
New Hampshire	32	32	100	0	0.0
New Mexico	148	127	85.8	21	14.2
New York	2,123	1,836	86.5	287	13.5
North Carolina	1,395	1,120	80.3	275	19.7
North Dakota	36	31	86.1	5	13.9
Ohio	909	760	83.6	149	16.4
Oklahoma	375	296	78.9	79	21.1
Oregon	198	156	78.8	42	21.2
Rhode Island	67	51	76.1	16	23.9
South Carolina	667	568	85.2	99	14.8
South Dakota	30	25	83.3	5	16.7
Tennessee	833	584	70.1	249	29.9
Texas	4,226	3,306	78.2	920	21.8
Utah	131	110	84.0	21	16.0
Virginia	801	637	79.5	164	20.5
Washington	458	403	88.0	55	12.0
West Virginia	148	108	73.0	40	27.0
Wisconsin	256	228	89.1	28	10.9
Wyoming	7	6	85.7	1	14.3
Total	32,895	27,123	82.5	5,772	17.5

Table 2b. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2021 through March 2022—45 states and the District of Columbia (preliminary) (cont)

Area of residence	No.	Total diagnoses		≥1 CD4 or VL tests		No CD4 or VL test	
		No.	%	No.	%	No.	%
2022 (January–March)							
Alabama	97	18	18.6	79	81.4		
Alaska	5	4	80.0	1	20.0		
Arizona	242	197	81.4	45	18.6		
Arkansas	86	58	67.4	28	32.6		
California	867	737	85.0	130	15.0		
Colorado	102	87	85.3	15	14.7		
Connecticut	50	42	84.0	8	16.0		
Delaware	23	21	91.3	2	8.7		
District of Columbia	25	19	76.0	6	24.0		
Florida	1,565	1,374	87.8	191	12.2		
Georgia	402	340	84.6	62	15.4		
Hawaii	11	11	100	0	0.0		
Illinois	265	224	84.5	41	15.5		
Indiana	136	110	80.9	26	19.1		
Iowa	19	18	94.7	1	5.3		
Kansas	36	31	86.1	5	13.9		
Louisiana	207	172	83.1	35	16.9		
Maine	7	7	100	0	0.0		
Maryland	190	173	91.1	17	8.9		
Massachusetts	71	63	88.7	8	11.3		
Michigan	143	131	91.6	12	8.4		
Minnesota	62	50	80.6	12	19.4		
Mississippi	74	31	41.9	43	58.1		
Missouri	127	103	81.1	24	18.9		
Montana	5	4	80.0	1	20.0		
Nebraska	32	28	87.5	4	12.5		
Nevada	124	113	91.1	11	8.9		
New Hampshire	4	3	75.0	1	25.0		
New Mexico	16	15	93.8	1	6.3		
New York	496	432	87.1	64	12.9		
North Carolina	374	304	81.3	70	18.7		
North Dakota	1	0	0.0	1	100		
Ohio	200	175	87.5	25	12.5		
Oklahoma	76	58	76.3	18	23.7		
Oregon	65	54	83.1	11	16.9		
Rhode Island	10	10	100	0	0.0		
South Carolina	173	134	77.5	39	22.5		
South Dakota	6	6	100	0	0.0		
Tennessee	210	155	73.8	55	26.2		
Texas	901	654	72.6	247	27.4		
Utah	22	22	100	0	0.0		
Virginia	198	167	84.3	31	15.7		
Washington	98	88	89.8	10	10.2		
West Virginia	38	22	57.9	16	42.1		
Wisconsin	59	53	89.8	6	10.2		
Wyoming	4	3	75.0	1	25.0		
Total	7,924	6,521	82.3	1,403	17.7		

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/ μ L) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only]; NHSS, National HIV Surveillance System [footnotes only].

Note. Data are based on residence at diagnosis of HIV infection. Data are for cases reported to CDC through June 2022, are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting delay to account for delays in reporting of laboratory results to NHSS; therefore, data on linkage to HIV medical care in these surveillance tables are for persons with HIV diagnosed during January 2021 through March 2022 and reported to NHSS through June 2022. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Area without laws: Idaho. Areas with incomplete reporting: Kentucky, New Jersey, Pennsylvania (excluding Philadelphia), and Vermont.

Table 2c. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2021 through March 2022—Ending the HIV Epidemic Phase I jurisdictions (preliminary)

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
2021					
Arizona					
Maricopa County	526	456	86.7	70	13.3
California					
Alameda County	186	166	89.2	20	10.8
Los Angeles County	1,381	1,150	83.3	231	16.7
Orange County	265	231	87.2	34	12.8
Riverside County	245	191	78.0	54	22.0
Sacramento County	150	136	90.7	14	9.3
San Bernardino County	295	225	76.3	70	23.7
San Diego County	285	240	84.2	45	15.8
San Francisco County	188	178	94.7	10	5.3
District of Columbia	197	160	81.2	37	18.8
Florida					
Broward County	652	548	84.0	104	16.0
Duval County	295	235	79.7	60	20.3
Hillsborough County	315	257	81.6	58	18.4
Miami-Dade County	1,201	1,034	86.1	167	13.9
Orange County	455	380	83.5	75	16.5
Palm Beach County	317	265	83.6	52	16.4
Pinellas County	127	104	81.9	23	18.1
Georgia					
Cobb County	143	121	84.6	22	15.4
DeKalb County	312	266	85.3	46	14.7
Fulton County	528	443	83.9	85	16.1
Gwinnett County	138	126	91.3	12	8.7
Illinois					
Cook County	748	646	86.4	102	13.6
Indiana					
Marion County	217	172	79.3	45	20.7
Louisiana					
East Baton Rouge Parish	149	117	78.5	32	21.5
Orleans Parish	147	133	90.5	14	9.5
Maryland					
Baltimore City	159	136	85.5	23	14.5
Montgomery County	100	88	88.0	12	12.0
Prince George's County	231	199	86.1	32	13.9
Massachusetts					
Suffolk County	128	123	96.1	5	3.9
Michigan					
Wayne County	251	213	84.9	38	15.1
Nevada					
Clark County	442	384	86.9	58	13.1
New York					
Bronx County	419	365	87.1	54	12.9
Kings County	439	379	86.3	60	13.7
New York County	324	269	83.0	55	17.0
Queens County	336	289	86.0	47	14.0

Table 2c. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2021 through March 2022—Ending the HIV Epidemic Phase I jurisdictions (preliminary) (cont)

Area of residence	Total diagnoses No.	≥1 CD4 or VL tests		No CD4 or VL test	
		No.	%	No.	%
2021 (cont)					
North Carolina					
Mecklenburg County	278	226	81.3	52	18.7
Ohio					
Cuyahoga County	165	147	89.1	18	10.9
Franklin County	187	163	87.2	24	12.8
Hamilton County	124	110	88.7	14	11.3
Pennsylvania					
Philadelphia County	369	310	84.0	59	16.0
Tennessee					
Shelby County	298	181	60.7	117	39.3
Texas					
Bexar County	333	265	79.6	68	20.4
Dallas County	780	607	77.8	173	22.2
Harris County	1,143	867	75.9	276	24.1
Tarrant County	308	238	77.3	70	22.7
Travis County	226	185	81.9	41	18.1
Washington					
King County	219	195	89.0	24	11.0

Table 2c. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2021 through March 2022—Ending the HIV Epidemic Phase I jurisdictions (preliminary) (cont)

Area of residence	Total diagnoses No.	≥1 CD4 or VL tests		No CD4 or VL test		
		No.	%	No.	%	
2022 (January–March)						
Arizona						
Maricopa County	158	133	84.2	25	15.8	
California						
Alameda County	45	40	88.9	5	11.1	
Los Angeles County	289	238	82.4	51	17.6	
Orange County	55	45	81.8	10	18.2	
Riverside County	68	55	80.9	13	19.1	
Sacramento County	15	15	100	0	0.0	
San Bernardino County	63	49	77.8	14	22.2	
San Diego County	1	0	0.0	1	100	
San Francisco County	49	48	98.0	1	2.0	
District of Columbia	25	19	76.0	6	24.0	
Florida						
Broward County	218	191	87.6	27	12.4	
Duval County	87	72	82.8	15	17.2	
Hillsborough County	104	92	88.5	12	11.5	
Miami-Dade County	451	403	89.4	48	10.6	
Orange County	154	131	85.1	23	14.9	
Palm Beach County	99	89	89.9	10	10.1	
Pinellas County	48	38	79.2	10	20.8	
Georgia						
Cobb County	20	19	95.0	1	5.0	
DeKalb County	60	46	76.7	14	23.3	
Fulton County	97	83	85.6	14	14.4	
Gwinnett County	21	19	90.5	2	9.5	
Illinois						
Cook County	191	164	85.9	27	14.1	
Indiana						
Marion County	48	40	83.3	8	16.7	
Louisiana						
East Baton Rouge Parish	33	27	81.8	6	18.2	
Orleans Parish	37	33	89.2	4	10.8	
Maryland						
Baltimore City	58	54	93.1	4	6.9	
Montgomery County	24	22	91.7	2	8.3	
Prince George's County	45	40	88.9	5	11.1	
Massachusetts						
Suffolk County	21	19	90.5	2	9.5	
Michigan						
Wayne County	58	53	91.4	5	8.6	
Nevada						
Clark County	109	100	91.7	9	8.3	
New York						
Bronx County	96	81	84.4	15	15.6	
Kings County	100	93	93.0	7	7.0	
New York County	89	73	82.0	16	18.0	
Queens County	75	66	88.0	9	12.0	

Table 2c. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2021 through March 2022—Ending the HIV Epidemic Phase I jurisdictions (preliminary) (cont)

Area of residence	Total diagnoses No.	≥1 CD4 or VL tests		No CD4 or VL test	
		No.	%	No.	%
2022 (January–March) (cont)					
North Carolina					
Mecklenburg County	68	53	77.9	15	22.1
Ohio					
Cuyahoga County	30	25	83.3	5	16.7
Franklin County	34	33	97.1	1	2.9
Hamilton County	27	25	92.6	2	7.4
Pennsylvania					
Philadelphia County	105	86	81.9	19	18.1
Tennessee					
Shelby County	80	53	66.3	27	33.8
Texas					
Bexar County	84	62	73.8	22	26.2
Dallas County	180	130	72.2	50	27.8
Harris County	285	201	70.5	84	29.5
Tarrant County	70	42	60.0	28	40.0
Travis County	48	40	83.3	8	16.7
Washington					
King County	48	44	91.7	4	8.3

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only]; NHSS, National HIV Surveillance System [footnotes only].

Note. Data are based on residence at diagnosis of HIV infection. Data are for cases reported to CDC through June 2022, are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting delay to account for delays in reporting of laboratory results to NHSS; therefore, data on linkage to HIV medical care in these surveillance tables are for persons with HIV diagnosed during January 2021 through March 2022 and reported to NHSS through June 2022. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Area without laws: Idaho. Areas with incomplete reporting: Kentucky, New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico (San Juan).

Table 3a. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through March 2022, among persons aged ≥16 years, by selected characteristics—United States (preliminary)

	Persons prescribed PrEP ^a No.	Persons with PrEP indications ^b No.	PrEP coverage ^c %
	2019		
Sex at birth			
Male	254,133	989,200	25.7
Female	21,039	227,010	9.3
Age (yr)			
16–24	37,630	246,290	15.3
25–34	111,779	434,680	25.7
35–44	64,129	238,470	26.9
45–54	37,472	173,420	21.6
≥55	24,217	123,350	19.6
Race/ethnicity^d			
Black/African American	37,248	468,540	7.9
Hispanic/Latino ^e	45,473	312,820	14.5
Other	12,330	131,180	9.4
White	180,264	300,650	60.0
Total	275,315	1,216,210	22.6
2020 (COVID-19 pandemic)			
Sex at birth			
Male	277,380	989,200	28.0
Female	23,584	227,010	10.4
Age (yr)			
16–24	37,743	246,290	15.3
25–34	120,385	434,680	27.7
35–44	71,964	238,470	30.2
45–54	40,546	173,420	23.4
≥55	30,290	123,350	24.6
Race/ethnicity^d			
Black/African American	43,171	468,540	9.2
Hispanic/Latino ^e	51,271	312,820	16.4
Other	12,842	131,180	9.8
White	193,746	300,650	64.4
Total	301,030	1,216,210	24.8
2021			
Sex at birth			
Male	338,466	989,200	34.2
Female	28,065	227,010	12.4
Age (yr)			
16–24	48,620	246,290	19.7
25–34	146,029	434,680	33.6
35–44	88,719	238,470	37.2
45–54	46,370	173,420	26.7
≥55	36,903	123,350	29.9
Race/ethnicity^d			
Black/African American	51,891	468,540	11.1
Hispanic/Latino ^e	63,953	312,820	20.4
Other	15,724	131,180	12.0
White	235,251	300,650	78.2
Total	366,819	1,216,210	30.2

Table 3a. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through March 2022, among persons aged ≥16 years, by selected characteristics—United States (preliminary) (cont)

	Persons prescribed PrEP ^a No.	Persons with PrEP indications ^b No.	PrEP coverage ^c %
	2022 (January–March)		
Sex at birth			
Male	237,046	989,200	24.0
Female	14,323	227,010	6.3
Age (yr)			
16–24	23,930	246,290	9.7
25–34	96,753	434,680	22.3
35–44	67,079	238,470	28.1
45–54	34,315	173,420	19.8
≥55	29,258	123,350	23.7
Race/ethnicity^d			
Black/African American	32,541	468,540	6.9
Hispanic/Latino ^e	42,458	312,820	13.6
Other	10,907	131,180	8.3
White	165,503	300,650	55.0
Total	251,410	1,216,210	20.7

Abbreviations: PrEP, preexposure prophylaxis; FDA, Food and Drug Administration [footnotes only].

Note. Data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

^a Estimated by using data from IQVIA pharmacy database reported through March 2022 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported; thus, values may not sum to column total.

^b Estimated by using 2018 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported; thus, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator.

^c PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

^d Race/ethnicity data were only available for <40% of persons prescribed PrEP in each year. Number prescribed PrEP and PrEP coverage for race/ethnicity reported in the table were adjusted applying the distribution of records with known race/ethnicity to records with missing race/ethnicity.

^e Hispanic/Latino persons can be of any race.

Table 3b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through March 2022, among persons aged ≥ 16 years, by area of residence—United States and Puerto Rico (preliminary)

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
2019			
Alabama	1,833	11,020	16.6
Alaska	228	1,780	12.8
Arizona	4,580	25,780	17.8
Arkansas	730	5,130	14.2
California	41,611	165,030	25.2
Colorado	4,407	25,120	17.5
Connecticut	2,667	9,560	27.9
Delaware	473	4,400	10.8
District of Columbia	5,884	12,950	45.4
Florida	21,771	125,330	17.4
Georgia	8,647	39,030	22.2
Hawaii	817	4,360	18.7
Idaho	474	4,790	9.9
Illinois	16,656	55,860	29.8
Indiana	2,981	22,170	13.4
Iowa	1,428	4,760	30.0
Kansas	905	5,060	17.9
Kentucky	1,607	12,990	12.4
Louisiana	3,945	15,920	24.8
Maine	649	3,950	16.4
Maryland	4,930	27,300	18.1
Massachusetts	9,306	24,900	37.4
Michigan	4,351	29,570	14.7
Minnesota	4,203	21,720	19.4
Mississippi	952	4,530	21.0
Missouri	3,480	18,370	18.9
Montana	267	2,290	11.7
Nebraska	619	2,180	28.4
Nevada	2,184	11,390	19.2
New Hampshire	614	3,020	20.3
New Jersey	5,684	25,280	22.5
New Mexico	1,074	6,800	15.8
New York	35,317	72,640	48.6
North Carolina	5,403	32,490	16.6
North Dakota	191	1,520	12.6
Ohio	6,116	40,320	15.2
Oklahoma	1,158	11,030	10.5
Oregon	3,391	19,750	17.2
Pennsylvania	10,109	36,490	27.7
Puerto Rico	330	9,700	3.4
Rhode Island	1,074	3,880	27.7
South Carolina	1,724	10,390	16.6
South Dakota	152	910	16.7
Tennessee	3,894	22,460	17.3
Texas	23,126	123,790	18.7
Utah	2,037	6,840	29.8
Vermont	338	1,060	31.9
Virginia	4,404	31,430	14.0
Washington	9,886	40,050	24.7
West Virginia	567	5,250	10.8
Wisconsin	2,468	12,980	19.0
Wyoming	94	890	10.6

Table 3b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through March 2022, among persons aged ≥16 years, by area of residence—United States and Puerto Rico (preliminary) (cont)

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
2020 (COVID-19 pandemic)			
Alabama	1,909	11,020	17.3
Alaska	244	1,780	13.7
Arizona	5,060	25,780	19.6
Arkansas	868	5,130	16.9
California	42,277	165,030	25.6
Colorado	4,792	25,120	19.1
Connecticut	2,472	9,560	25.9
Delaware	471	4,400	10.7
District of Columbia	5,969	12,950	46.1
Florida	34,567	125,330	27.6
Georgia	9,772	39,030	25.0
Hawaii	901	4,360	20.7
Idaho	663	4,790	13.8
Illinois	15,979	55,860	28.6
Indiana	3,199	22,170	14.4
Iowa	1,561	4,760	32.8
Kansas	947	5,060	18.7
Kentucky	1,660	12,990	12.8
Louisiana	3,593	15,920	22.6
Maine	671	3,950	17.0
Maryland	4,806	27,300	17.6
Massachusetts	9,376	24,900	37.7
Michigan	4,669	29,570	15.8
Minnesota	4,213	21,720	19.4
Mississippi	1,100	4,530	24.3
Missouri	3,564	18,370	19.4
Montana	295	2,290	12.9
Nebraska	720	2,180	33.0
Nevada	2,505	11,390	22.0
New Hampshire	645	3,020	21.4
New Jersey	5,918	25,280	23.4
New Mexico	1,236	6,800	18.2
New York	34,152	72,640	47.0
North Carolina	6,154	32,490	18.9
North Dakota	187	1,520	12.3
Ohio	6,829	40,320	16.9
Oklahoma	1,527	11,030	13.8
Oregon	3,818	19,750	19.3
Pennsylvania	10,567	36,490	29.0
Puerto Rico	367	9,700	3.8
Rhode Island	1,149	3,880	29.6
South Carolina	2,115	10,390	20.4
South Dakota	146	910	16.0
Tennessee	5,170	22,460	23.0
Texas	27,528	123,790	22.2
Utah	2,374	6,840	34.7
Vermont	321	1,060	30.3
Virginia	5,120	31,430	16.3
Washington	10,062	40,050	25.1
West Virginia	522	5,250	9.9
Wisconsin	2,529	12,980	19.5
Wyoming	99	890	11.1

Table 3b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through March 2022, among persons aged ≥16 years, by area of residence—United States and Puerto Rico (preliminary) (cont)

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
2021			
Alabama	2,772	11,020	25.2
Alaska	305	1,780	17.1
Arizona	6,575	25,780	25.5
Arkansas	1,285	5,130	25.0
California	50,334	165,030	30.5
Colorado	6,194	25,120	24.7
Connecticut	3,054	9,560	31.9
Delaware	641	4,400	14.6
District of Columbia	6,780	12,950	52.4
Florida	42,685	125,330	34.1
Georgia	12,206	39,030	31.3
Hawaii	1,137	4,360	26.1
Idaho	873	4,790	18.2
Illinois	18,417	55,860	33.0
Indiana	4,274	22,170	19.3
Iowa	1,962	4,760	41.2
Kansas	1,277	5,060	25.2
Kentucky	2,237	12,990	17.2
Louisiana	4,184	15,920	26.3
Maine	911	3,950	23.1
Maryland	5,809	27,300	21.3
Massachusetts	10,184	24,900	40.9
Michigan	5,925	29,570	20.0
Minnesota	5,270	21,720	24.3
Mississippi	1,602	4,530	35.4
Missouri	4,176	18,370	22.7
Montana	395	2,290	17.2
Nebraska	1,010	2,180	46.3
Nevada	4,896	11,390	43.0
New Hampshire	799	3,020	26.5
New Jersey	7,284	25,280	28.8
New Mexico	1,597	6,800	23.5
New York	39,146	72,640	53.9
North Carolina	7,971	32,490	24.5
North Dakota	248	1,520	16.3
Ohio	8,501	40,320	21.1
Oklahoma	2,333	11,030	21.2
Oregon	4,683	19,750	23.7
Pennsylvania	13,074	36,490	35.8
Puerto Rico	608	9,700	6.3
Rhode Island	1,515	3,880	39.0
South Carolina	2,960	10,390	28.5
South Dakota	217	910	23.8
Tennessee	7,247	22,460	32.3
Texas	34,787	123,790	28.1
Utah	3,276	6,840	47.9
Vermont	484	1,060	45.7
Virginia	6,288	31,430	20.0
Washington	11,392	40,050	28.4
West Virginia	711	5,250	13.5
Wisconsin	2,823	12,980	21.7
Wyoming	141	890	15.8

Table 3b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through March 2022, among persons aged ≥16 years, by area of residence—United States and Puerto Rico (preliminary) (cont)

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
2022 (January–March)			
Alabama	2,046	11,020	18.6
Alaska	204	1,780	11.5
Arizona	4,849	25,780	18.8
Arkansas	882	5,130	17.2
California	35,695	165,030	21.6
Colorado	4,171	25,120	16.6
Connecticut	2,215	9,560	23.2
Delaware	499	4,400	11.3
District of Columbia	5,046	12,950	39.0
Florida	24,846	125,330	19.8
Georgia	8,447	39,030	21.6
Hawaii	871	4,360	20.0
Idaho	617	4,790	12.9
Illinois	13,672	55,860	24.5
Indiana	3,092	22,170	13.9
Iowa	1,303	4,760	27.4
Kansas	891	5,060	17.6
Kentucky	1,605	12,990	12.4
Louisiana	2,688	15,920	16.9
Maine	640	3,950	16.2
Maryland	3,962	27,300	14.5
Massachusetts	7,287	24,900	29.3
Michigan	4,015	29,570	13.6
Minnesota	3,846	21,720	17.7
Mississippi	962	4,530	21.2
Missouri	2,902	18,370	15.8
Montana	256	2,290	11.2
Nebraska	753	2,180	34.5
Nevada	1,950	11,390	17.1
New Hampshire	557	3,020	18.4
New Jersey	4,991	25,280	19.7
New Mexico	1,132	6,800	16.6
New York	27,437	72,640	37.8
North Carolina	5,669	32,490	17.4
North Dakota	182	1,520	12.0
Ohio	6,146	40,320	15.2
Oklahoma	1,557	11,030	14.1
Oregon	3,330	19,750	16.9
Pennsylvania	9,420	36,490	25.8
Puerto Rico	367	9,700	3.8
Rhode Island	1,095	3,880	28.2
South Carolina	2,000	10,390	19.2
South Dakota	153	910	16.8
Tennessee	5,130	22,460	22.8
Texas	24,087	123,790	19.5
Utah	2,299	6,840	33.6
Vermont	324	1,060	30.6
Virginia	4,162	31,430	13.2
Washington	8,167	40,050	20.4
West Virginia	498	5,250	9.5
Wisconsin	1,879	12,980	14.5
Wyoming	98	890	11.0

Abbreviations: PrEP, preexposure prophylaxis; FDA, Food and Drug Administration [footnotes only].

Note. Data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

^a Estimated by using data from IQVIA pharmacy database reported through March 2022 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported; thus, values may not sum to column total.

^b Estimated by using 2018 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported; thus, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator.

^c PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through March 2022, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (preliminary)

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
2019			
Arizona			
Maricopa County	3,539	22,720	15.6
California			
Alameda County	2,167	8,930	24.3
Los Angeles County	13,685	67,450	20.3
Orange County	2,044	10,510	19.4
Riverside County	1,791	11,080	16.2
Sacramento County	956	5,920	16.1
San Bernardino County	750	11,890	6.3
San Diego County	3,727	14,500	25.7
San Francisco County	8,815	10,840	81.3
District of Columbia	5,884	12,950	45.4
Florida			
Broward County	3,831	20,470	18.7
Duval County	505	8,970	5.6
Hillsborough County	1,381	12,910	10.7
Miami-Dade County	6,494	21,760	29.8
Orange County	2,768	15,310	18.1
Palm Beach County	877	9,170	9.6
Pinellas County	1,133	9,530	11.9
Georgia			
Cobb County	563	3,070	18.3
DeKalb County	1,561	6,290	24.8
Fulton County	3,295	13,120	25.1
Gwinnett County	681	3,240	21.0
Illinois			
Cook County	13,617	39,060	34.9
Indiana			
Marion County	1,143	9,150	12.5
Louisiana			
East Baton Rouge Parish	495	1,810	27.3
Orleans Parish	1,519	4,590	33.1
Maryland			
Baltimore City	899	6,330	14.2
Montgomery County	900	5,770	15.6
Prince George's County	801	4,040	19.8
Massachusetts			
Suffolk County	2,765	6,520	42.4
Michigan			
Wayne County	1,200	9,270	12.9
Nevada			
Clark County	1,867	11,670	16.0
New Jersey			
Essex County	675	4,090	16.5
Hudson County	1,056	4,650	22.7

Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through March 2022, among persons aged ≥16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (preliminary) (cont)

Area of residence	Persons prescribed PrEP ^a No.	Persons with PrEP indications ^b No.	PrEP coverage ^c %
	2019 (cont)		
New York			
Bronx County	2,207	5,570	39.6
Kings County	7,569	15,650	48.4
New York County	14,134	15,540	91.0
Queens County	3,866	9,230	41.9
North Carolina			
Mecklenburg County	1,344	8,450	15.9
Ohio			
Cuyahoga County	958	7,520	12.7
Franklin County	2,037	11,620	17.5
Hamilton County	567	7,720	7.3
Pennsylvania			
Philadelphia County	3,635	9,840	36.9
Puerto Rico			
San Juan Municipio ^d	— ^d	2,190	n/a
Tennessee			
Shelby County	630	6,450	9.8
Texas			
Bexar County	1,522	11,920	12.8
Dallas County	4,107	28,670	14.3
Harris County	4,932	40,670	12.1
Tarrant County	1,461	11,340	12.9
Travis County	4,546	11,590	39.2
Washington			
King County	6,908	17,890	38.6

Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through March 2022, among persons aged ≥16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (preliminary) (cont)

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
2020 (COVID-19 pandemic)			
Arizona			
Maricopa County	3,889	22,720	17.1
California			
Alameda County	2,017	8,930	22.6
Los Angeles County	14,721	67,450	21.8
Orange County	2,209	10,510	21.0
Riverside County	1,925	11,080	17.4
Sacramento County	977	5,920	16.5
San Bernardino County	812	11,890	6.8
San Diego County	3,791	14,500	26.1
San Francisco County	8,109	10,840	74.8
District of Columbia	5,969	12,950	46.1
Florida			
Broward County	6,760	20,470	33.0
Duval County	735	8,970	8.2
Hillsborough County	1,537	12,910	11.9
Miami-Dade County	10,235	21,760	47.0
Orange County	3,872	15,310	25.3
Palm Beach County	3,011	9,170	32.8
Pinellas County	1,219	9,530	12.8
Georgia			
Cobb County	648	3,070	21.1
DeKalb County	1,721	6,290	27.4
Fulton County	3,593	13,120	27.4
Gwinnett County	790	3,240	24.4
Illinois			
Cook County	12,883	39,060	33.0
Indiana			
Marion County	1,205	9,150	13.2
Louisiana			
East Baton Rouge Parish	536	1,810	29.6
Orleans Parish	1,338	4,590	29.2
Maryland			
Baltimore City	855	6,330	13.5
Montgomery County	909	5,770	15.8
Prince George's County	821	4,040	20.3
Massachusetts			
Suffolk County	2,808	6,520	43.1
Michigan			
Wayne County	1,231	9,270	13.3
Nevada			
Clark County	2,105	11,670	18.0
New Jersey			
Essex County	709	4,090	17.3
Hudson County	1,057	4,650	22.7

Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through March 2022, among persons aged ≥16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (preliminary) (cont)

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
2020 (COVID-19 pandemic) (cont)			
New York			
Bronx County	2,034	5,570	36.5
Kings County	7,423	15,650	47.4
New York County	13,737	15,540	88.4
Queens County	3,803	9,230	41.2
North Carolina			
Mecklenburg County	1,576	8,450	18.7
Ohio			
Cuyahoga County	972	7,520	12.9
Franklin County	2,309	11,620	19.9
Hamilton County	636	7,720	8.2
Pennsylvania			
Philadelphia County	3,475	9,840	35.3
Puerto Rico			
San Juan Municipio ^d	— ^d	2,190	n/a
Tennessee			
Shelby County	809	6,450	12.5
Texas			
Bexar County	1,776	11,920	14.9
Dallas County	5,183	28,670	18.1
Harris County	5,987	40,670	14.7
Tarrant County	1,653	11,340	14.6
Travis County	5,062	11,590	43.7
Washington			
King County	6,975	17,890	39.0

Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through March 2022, among persons aged ≥16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (preliminary) (cont)

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
2021			
Arizona			
Maricopa County	5,025	22,720	22.1
California			
Alameda County	2,212	8,930	24.8
Los Angeles County	18,508	67,450	27.4
Orange County	2,843	10,510	27.1
Riverside County	2,530	11,080	22.8
Sacramento County	1,101	5,920	18.6
San Bernardino County	1,192	11,890	10.0
San Diego County	4,428	14,500	30.5
San Francisco County	8,155	10,840	75.2
District of Columbia	6,780	12,950	52.4
Florida			
Broward County	8,298	20,470	40.5
Duval County	900	8,970	10.0
Hillsborough County	2,022	12,910	15.7
Miami-Dade County	11,491	21,760	52.8
Orange County	4,707	15,310	30.7
Palm Beach County	2,760	9,170	30.1
Pinellas County	1,652	9,530	17.3
Georgia			
Cobb County	805	3,070	26.2
DeKalb County	2,067	6,290	32.9
Fulton County	4,271	13,120	32.6
Gwinnett County	996	3,240	30.7
Illinois			
Cook County	14,748	39,060	37.8
Indiana			
Marion County	1,588	9,150	17.4
Louisiana			
East Baton Rouge Parish	595	1,810	32.9
Orleans Parish	1,531	4,590	33.4
Maryland			
Baltimore City	986	6,330	15.6
Montgomery County	1,155	5,770	20.0
Prince George's County	995	4,040	24.6
Massachusetts			
Suffolk County	2,811	6,520	43.1
Michigan			
Wayne County	1,555	9,270	16.8
Nevada			
Clark County	4,303	11,670	36.9
New Jersey			
Essex County	839	4,090	20.5
Hudson County	1,289	4,650	27.7

Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through March 2022, among persons aged ≥16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (preliminary) (cont)

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
2021 (cont)			
New York			
Bronx County	2,092	5,570	37.6
Kings County	8,847	15,650	56.5
New York County	15,762	15,540	101.4
Queens County	4,288	9,230	46.5
North Carolina			
Mecklenburg County	1,965	8,450	23.3
Ohio			
Cuyahoga County	1,268	7,520	16.9
Franklin County	2,745	11,620	23.6
Hamilton County	816	7,720	10.6
Pennsylvania			
Philadelphia County	4,032	9,840	41.0
Puerto Rico			
San Juan Municipio	63	2,190	2.9
Tennessee			
Shelby County	938	6,450	14.5
Texas			
Bexar County	2,353	11,920	19.7
Dallas County	6,584	28,670	23.0
Harris County	7,487	40,670	18.4
Tarrant County	2,131	11,340	18.8
Travis County	5,812	11,590	50.1
Washington			
King County	7,649	17,890	42.8

Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through March 2022, among persons aged ≥16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (preliminary) (cont)

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
2022 (January–March)			
Arizona			
Maricopa County	3,777	22,720	16.6
California			
Alameda County	1,512	8,930	16.9
Los Angeles County	13,676	67,450	20.3
Orange County	1,921	10,510	18.3
Riverside County	1,849	11,080	16.7
Sacramento County	770	5,920	13.0
San Bernardino County	807	11,890	6.8
San Diego County	3,113	14,500	21.5
San Francisco County	5,792	10,840	53.4
District of Columbia	5,046	12,950	39.0
Florida			
Broward County	4,765	20,470	23.3
Duval County	598	8,970	6.7
Hillsborough County	1,439	12,910	11.1
Miami-Dade County	5,887	21,760	27.1
Orange County	3,098	15,310	20.2
Palm Beach County	1,231	9,170	13.4
Pinellas County	1,237	9,530	13.0
Georgia			
Cobb County	563	3,070	18.3
DeKalb County	1,458	6,290	23.2
Fulton County	3,017	13,120	23.0
Gwinnett County	696	3,240	21.5
Illinois			
Cook County	11,042	39,060	28.3
Indiana			
Marion County	1,184	9,150	12.9
Louisiana			
East Baton Rouge Parish	355	1,810	19.6
Orleans Parish	990	4,590	21.6
Maryland			
Baltimore City	667	6,330	10.5
Montgomery County	823	5,770	14.3
Prince George's County	646	4,040	16.0
Massachusetts			
Suffolk County	2,015	6,520	30.9
Michigan			
Wayne County	1,018	9,270	11.0
Nevada			
Clark County	1,573	11,670	13.5
New Jersey			
Essex County	555	4,090	13.6
Hudson County	919	4,650	19.8

Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through March 2022, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (preliminary) (cont)

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
2022 (January–March) (cont)			
New York			
Bronx County	1,199	5,570	21.5
Kings County	6,152	15,650	39.3
New York County	11,429	15,540	73.5
Queens County	3,011	9,230	32.6
North Carolina			
Mecklenburg County	1,411	8,450	16.7
Ohio			
Cuyahoga County	919	7,520	12.2
Franklin County	2,052	11,620	17.7
Hamilton County	571	7,720	7.4
Pennsylvania			
Philadelphia County	2,856	9,840	29.0
Puerto Rico			
San Juan Municipio	49	2,190	2.2
Tennessee			
Shelby County	622	6,450	9.6
Texas			
Bexar County	1,618	11,920	13.6
Dallas County	4,579	28,670	16.0
Harris County	5,222	40,670	12.8
Tarrant County	1,469	11,340	13.0
Travis County	4,181	11,590	36.1
Washington			
King County	5,598	17,890	31.3

Abbreviations: PrEP, preexposure prophylaxis; n/a, not available; FDA, Food and Drug Administration [footnotes only].

Note. Data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

^a Estimated by using data from IQVIA pharmacy database reported through March 2022 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported; thus, values may not sum to column total.

^b Estimated by using 2018 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported; thus, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator.

^c PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

^d Data value <40 was not reported due to unreliability.

Table 4. Ending the HIV Epidemic Phase I jurisdictions

Counties	Territories	States
Arizona	Puerto Rico^a	Alabama
Maricopa County	San Juan Municipio ^a	Arkansas
California		Kentucky ^a
Alameda County		Mississippi
Los Angeles County		Missouri
Orange County		Oklahoma
Riverside County		South Carolina
Sacramento County		
San Bernardino County		
San Diego County		
San Francisco County		
District of Columbia		
Florida		
Broward County		
Duval County		
Hillsborough County		
Miami-Dade County		
Orange County		
Palm Beach County		
Pinellas County		
Georgia		
Cobb County		
DeKalb County		
Fulton County		
Gwinnett County		
Illinois		
Cook County		
Indiana		
Marion County		
Louisiana		
East Baton Rouge Parish		
Orleans Parish		
Maryland		
Baltimore City		
Montgomery County		
Prince George's County		
Massachusetts		
Suffolk County		
Michigan		
Wayne County		
Nevada		
Clark County		
New Jersey^a		
Essex County ^a		
Hudson County ^a		
New York		
Bronx County		
Kings County		
New York County		
Queens County		

Table 4. Ending the HIV Epidemic Phase I jurisdictions (cont)

Counties	Territories	States
North Carolina		
Mecklenburg County		
Ohio		
Cuyahoga County		
Franklin County		
Hamilton County		
Pennsylvania^a		
Philadelphia County		
Tennessee		
Shelby County		
Texas		
Bexar County		
Dallas County		
Harris County		
Tarrant County		
Travis County		
Washington		
King County		

Abbreviations: CDC, the Centers for Disease Control and Prevention [footnotes only]; PrEP, preexposure prophylaxis [footnotes only]; CD4, CD4+ T-lymphocyte count (cells/µL) or percentage [footnotes only].

Note. For more information on the Ending the HIV Epidemic in the U.S. initiative, see <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview>.

^a Linkage to care data are not provided for states and associated jurisdictions that have incomplete reporting of laboratory data to CDC: Kentucky, New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.